Patients are at the heart of everything we do. We ensure their needs are met through providing innovative products and services that save or significantly enhance people’s lives and also by helping to detect, diagnose and treat disease. This underpins our strategy on both a global and local scale.
Corporate social responsibility is endorsed and ingrained at the highest level of Roche and is central to how we run our business. Supporting patient groups in Ireland who make a real difference to those you need it most is one of our greatest passions. This includes MS Ireland, The Marie Keating Foundation and the Irish Haemophilia Society to name a few.
We also believe we have a role to play in helping the communities in which we live and work. This takes the form of sharing our skills, providing opportunities, and promoting health and wellbeing.
We do business in a responsible and ethical manner and with a commitment to sustainable development, respecting the needs of the individual, the society and the environment.
At Roche we have always been committed to maintaining the highest standards of ethical conduct in our business and all our dealings. How we operate is as important as what we do and why we do it.
Healthcare practitioners trust us with their reputation, patients trust us with their health and communities trust us with their future. This is the basis upon which we have built our focus on long-term value creation. Through stringent internal controls and a healthy ethical culture, we ensure the future prosperity of our business and that of our stakeholders.
Our Code of Conduct provides all Roche employees, and others who act for us, with a clear understanding of the principles of business conduct, standards, and ethical behaviours that are expected of them. We entrust each and every member of our global team to uphold and abide by the principles and standards the Code sets out. All employees engage in mandatory training to ensure they fully understand the Roche Code of Conduct.
Our Performance Management Principles ensure that employee compensation addresses not only the results they achieve, but also how they achieve them. In particular, the principles consider whether employees’ performance reflects our Roche Values.
All member companies of the Irish Pharmaceutical Healthcare Association (IPHA) are subject to the IPHA Code of Practice for the pharmaceutical industry. The Code of Practice is in place to ensure the highest possible standards in how member companies conduct their business in Ireland. Roche, as a member of IPHA, is committed to adhering to the Code of Practice in all areas of our business and in all interactions with our stakeholders. We are also committed to bringing greater transparency to our relationships with healthcare professionals and healthcare organisations and we believe that the disclosure of transfers of value helps build an understanding of the collaboration with healthcare professionals and healthcare organisations and the recognition of its value to patient care.
Code of Practice for the Pharmaceutical Industry
The Code of Practice for the Pharmaceutical Industry was prepared by the Irish Pharmaceutical Healthcare Association (IPHA) with a view to securing the universal acceptance and adoption of high standards of conduct in the marketing of medicinal products to healthcare professionals, whether intended for use under medical supervision or otherwise.
Roche is committed to bringing greater transparency to our relationships with healthcare professionals and healthcare organisations and we believe that the disclosure of transfers of value is to build understanding of the collaboration with healthcare professionals and healthcare organisations and the recognition of its value to patient care.
For over 120 years Roche has been committed to improving lives. The long-term thinking of our founders has allowed us to stay true to this vision. Our greatest contribution to society is lasting innovation. When acting sustainably, we also aim to provide a rewarding workplace, be a trustworthy partner and engage with the community.
Our primary contribution to healthcare is to discover and develop medicines and diagnostics that significantly improve people’s lives. This entails a commitment to working with many different partners to continuously and sustainably reduce the barriers that prevent or impede access to our products. Roche has received the Gold class award from RobecoSAM, the Dow Jones Sustainability Indices (DJSI) rating agency, within the pharmaceuticals, biotechnology and life sciences Industry for eleven years in a row.
Minimising our impact on the environment goes beyond the day-to-day operation of our business – we also build it into the design of our products as well as the management of our products at the end of their lives. It is important to us that our medicines and diagnostics products are developed, produced, used and managed at end of life in a responsible way.
As a leading healthcare company dedicated to tackling some of the world’s most aggressive diseases, Roche inherently believes in improving the quality of people’s lives.